MAPT and medulloblastoma: To examine the effect of NCT-504 on Tau, we used human DAOY medulloblastoma cells, stably expressing dsRed-IRES-[WT]Tau:EGFP [48,49].Importantly, as measured by western blot analysis, treatment with NCT-504 for 12 hours resulted in a dose-dependent reduction in Tau-GFP, where 20 μM NCT-504 resulted in a 61% decrease (Figure 1C).